Comparison of Choroidal Morphological Changes Between Aflibercept 8 mg and Faricimab-svoa in Treatment-Naïve Polypoidal Choroidal Vasculopathy and Pachychoroid Neovasculopathy.

−13.8 ± 15.8 μm), although this did not reach statistical significance ( p = 0.153).

also in 75,281 other papers

35.3%) is consistent with the 1-year real-world comparative data of Cho et al., who found no statistically significant difference in polyp response between faricimab-svoa and aflibercept, although a numerical trend toward higher polyp closure with faricimab-svoa was noted [ 29 ].

also in 723 other papers